Head and neck basaloid squamous cell carcinoma (BSCC) has been considered a more aggressive variant of squamous cell carcinoma (SCC) with a poorer prognosis, although case-control studies have reached conflicting conclusions.
B asaloid squamous cell carcinoma (BSCC) is a rare variant of squamous cell carcinoma (SCC) that may arise in a variety of head and neck locations, including the oropharynx, hypopharynx, and larynx. 1 It is estimated that 2% of all head and neck SCCs and 5% of all node-positive SCCs are classified as BSCC. 2, 3 Compared with those with SCC, patients with head and neck BSCC more often have cervical lymph node involvement and distant metastasis. 4, 5 Basaloid squamous cell carcinoma has an ulcerating infiltrative growth pattern, peripheral nuclear palisading, increased mitotic activity, and poor differentiation and may be mistaken for adenoid cystic carcinoma. 6, 7 Like SCC, BSCC is associated with alcohol and tobacco use and is often seen in men in their sixth and seventh decades of life. 8, 9 Since first being described by Wain et al 10 in 1986, BSCC has often been considered to exhibit more aggressive behavior and to have a poorer prognosis than SCC. However, conflicting data exist regarding the prognostic significance of BSCC. Two small case-control studies of BSCC vs SCC of the head and neck reached different conclusions, one suggesting a detriment in survival 11 and the other no statistical difference from moderate or poorly differentiated SCC. 3 Recent investigations have shown an association between human papillomavirus (HPV) and BSCC, particularly HPV type 16. 12 It has also been suggested that BSCC may be a heterogeneous entity, with the subset of BSCC associated with HPV having a more favorable prognosis than those that are not. 13 Although several reports suggest that patients with BSCC more often have advanced-stage disease, it is not yet clear if BSCC is an independent prognostic factor after accounting for multiple other variables that influence clinical outcomes in head and neck cancer. Given the conflicting results of small institutional case-control studies and the relative rarity of BSCC, we sought to use a large population-based registry to explore the effect of BSCC on overall survival in head and neck cancer.
Methods
The Surveillance, Epidemiology, and End Results (SEER) program of the National Cancer Institute was used. Analyses from SEER are exempt from review at our institutional review board, given the patient deidentified nature of the data. The SEER 18 Registrar Research Database was queried from January 2004 through December 2009 to obtain individual case data on all patients diagnosed with SCC (microinvasive, large cell nonkeratinizing, SCC grade 3, SCC with horn formation, keratinizing SCC not otherwise specified, and SCC not otherwise specified) or BSCC of the oral cavity, oropharynx, larynx, or hypopharynx. Patient data available for abstraction included age at diagnosis, race, sex, primary site, American Joint Committee on Cancer stage, TNM stage, primary tumor size, use of surgery to the primary tumor site, use of radiation and sequencing with surgery, lymph node dissection, and history of prior malignant neoplasms.
Statistical analysis of data was performed with SPSS, version 20 (SPSS, Inc). Patients were divided into 3 cohorts: those with disease in the oral cavity, oropharynx, and larynx or hypopharynx. Patients who had missing staging information (Tx, Nx, and Mx were included), had distant metastasis at presentation, or did not receive curative treatment (no surgery or radiation) were excluded from this study. Tables 1, 2 , and 3.
Oral Cavity Analysis
Of the 12 493 patients with disease in the oral cavity, 12 417 had SCC and 76 had BSCC. Compared with those with SCC, a higher proportion of patients with BSCC were black (14.7% vs 6.0%, P = .002), were male (73.7% vs 61.7%, P = .03), had highgrade tumors (75.0% vs 17.2%, P < .001), had stage IV tumors (36.8% vs 23.8%, P = .047), and had a lymph node dissection (59.2% vs 44.4%, P = .01). Univariate analysis identified patient age, race, tumor grade, group stage, TNM stage, size, therapeutic treatment type, lymph node dissection, and prior cancer diagnosis as significant variables influencing overall survival. The 3-year overall survival for those with SCC was 62.3% vs 53.9% for BSCC (P = .28). A Cox proportional hazards regression model was developed including all variables from the univariate analysis with P < .20. All variables from the univariate analysis except histology met this threshold for inclusion in the multivariate analysis. In the multivariate analysis, all variables retained a statistically significant association with overall survival except M status (M0 vs Mx) and prior cancer diagnosis ( Table 4) .
Oropharynx Analysis
Of the 13 908 patients with disease in the oropharynx, 13 422 had SCC and 486 had BSCC. Compared with those with SCC, a higher proportion of patients with BSCC had high-grade tumors (90.9% vs 47.0%, P < .001) and a lymph node dissection (39.3% vs 33.1%, P = .01). A lower proportion of patients with BSCC had T3 or T4 disease (24.7% vs 30.9%, P = .04), and the mean tumor size for BSCC was slightly smaller than for SCC (2.7 vs 3.0 cm, P = .045).
Univariate analysis identified patient race, age, tumor histology, tumor grade, group stage, TNM stage, tumor size, therapeutic treatment type, lymph node dissection, and prior cancer diagnosis as significant variables for overall survival. In the univariate analysis, the 3-year overall survival was 79.8% (95% CI, 75.5%-84.1%) for patients with BSCC and 65.1% (64.1%-66.1%) for those with SCC (P < .001). A Cox proportional hazards regression model was developed including all variables from the univariate analysis with P < .20. All variables from the univariate analysis met this threshold for inclusion in the multivariate analysis. In the multivariate analysis, all variables retained a statistically significant association with overall sur- 
Larynx and Hypopharynx Analysis
Of the 7795 patients with disease in either the larynx or the hypopharynx, 7715 had SCC and 80 had BSCC. Compared with those with SCC, a higher proportion of patients with BSCC had disease in the hypopharynx (70.0% vs 27.0%, P < .001), a highgrade tumor (82.0% vs 21.3%, P < .001), stage IV disease (50.0% vs 25.6%, P < .001), T3 or T4 disease (36.3% vs 28.4%, P < .001), a lymph node dissection (31.3% vs 12.0%, P < .001), and a prior cancer diagnosis (35.0% vs 16.9%, P < .001). A greater proportion of patients with BSCC had nodal disease (51.3% vs 25.6%, P < .001) and fewer received postoperative radiation therapy (22.8% vs 31.3%, P = .03). Univariate analysis identified patient sex, age, tumor histology, tumor grade, group stage, T stage, N stage, tumor size, therapeutic treatment, lymph node dissection, and prior cancer diagnosis as significant variables for overall survival. In the univariate analysis, the 3-year overall survival was 58.1% (95% CI, 44.6%-71.6%) for patients with BSCC and 67.0% (65.8%-68.2%) for those with SCC (P = .03). A Cox proportional hazards regression model was developed including all variables from the univariate analysis with P < .20. All variables from the univariate analysis except race and M stage met this threshold for inclusion in the multivariate analysis. In the multivariate analysis, group stage, T stage, N stage, tumor size, lymph node dissection, and age statistically significantly influenced overall survival ( Table 6 ). 
Discussion
Our analysis suggests that BSCC is not an independent adverse prognostic factor compared with SCC. In this large population-based registry across all cohorts, patients with BSCC had a higher-grade tumor and were more often treated with lymph node dissection, confirming findings of several institutional experiences. In the oral cavity and the larynx and hypopharynx, patients with BSCC did not have a statistically significantly higher hazard ratio for death compared with those with SCC. Indeed, in the oropharynx, patients with BSCC had a statistically significantly lower hazard ratio for death than did those with SCC. The association between HPV and BSCC in the oropharynx likely explains the relatively favorable outcomes for these patients. The incidence of HPV-associated tumors appears to be increasing, 14 potentially due to increased recognition of the entity or to changing demographics and sexual practices. Since HPV seems to be associated with at least a subset of BSCC, it may be that the prognostic significance of BSCC is changing. Older series of patients with BSCC may represent a more unfavorable population of tumors less commonly driven by HPV compared with our patient population from January 2004 through December 2009, an era of increasing HPV prevalence. While some have advocated for more aggressive clinical treatment of patients with BSCC, including the suggestion of mandatory neck dissections and postoperative chemoradiation in all patients, 11 our data do not support altering current standards of care for treating patients with head and neck cancer based purely on the BSCC. After controlling for disease and treatment variables, including neck dissection and radiotherapy, BSCC did not have an independent adverse prognostic effect on overall survival. To our knowledge, this is the largest study to date of the outcomes of patients with BSCC compared with those of patients with SCC. Of note, the SEER database has limitations, tations, our data suggest no indication of a poorer prognosis for patients who have BSCC compared with those who have SCC.
In conclusion, compared with those with SCC, patients with head and neck BSCC more often had a high-grade tumor and underwent lymph node dissection. After controlling for multiple patient, disease, and treatment characteristics, patients with BSCC had no statistically significant difference in the hazard ratio for death compared with patients with SCC in the oral cavity and the larynx and hypopharynx and had a statistically significantly lower hazard ratio for death in the oropharynx. These findings suggest that BSCC histology is not an independent adverse prognostic factor in head and neck cancer. 
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